Vertex Pharma (VRTX) Misses Q2 EPS by 113c; raises guidance
Tweet
Share
E-mail
Get Alerts VRTX Hot Sheet
Price: $499.40 -0.05%
Revenue Growth %: +8.4%
Financial Fact:
Net loss attributable to Vertex: -38.84M
Today's EPS Names:
DTGI, CRMT, STZ, More
Revenue Growth %: +8.4%
Financial Fact:
Net loss attributable to Vertex: -38.84M
Today's EPS Names:
DTGI, CRMT, STZ, More
Join SI Premium – FREE
Vertex Pharma (NASDAQ: VRTX) reported Q2 EPS of ($12.83), $1.13 worse than the analyst estimate of ($11.70). Revenue for the quarter came in at $2.65 billion versus the consensus estimate of $2.66 billion.
GUIDANCE:
Vertex Pharma sees FY2024 revenue of $10.65-10.85 billion, versus the consensus of $10.762 billion.
For earnings history and earnings-related data on Vertex Pharma (VRTX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- NPR retracts story about Justice Alito retiring from Supreme Court
- ECB policymakers debating doubling banks' minimum reserve requirement to 2% from 1% - Reuters
- Blackline Safety goes private after Francisco Partners acquisition
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
